Hamed Hanafi, NovaResp Technologies - AI-Enabled Software for Obstructive Sleep Apnea | LSI USA '24

Hamed Hanafi  0:04  
My name is Hamed Hanafi, and I'm the founder of NovaResp, the company that is revolutionizing the treatment of obstructive sleep apnea through comfort innovation. Obstructive Sleep Apnea is the blockage of airway that could last periods of 10 seconds or up to two minutes. This could happen hundreds of times a night. The comorbidities associated to obstructive sleep apnea are type two diabetes, higher chances of heart attacks, higher chances of strokes, depression, higher chance of car accidents, it is estimated that 1 billion people globally are affected by it. It is growing to be 1.4 billion people by 2050 80% of these patients are currently undiagnosed. And from those that are diagnosed, over half of them refuse to use therapy there non adherence to therapy. That would be CPAP therapy. Is there competition to see perhaps Yes, there is pills and oral appliances that don't work on severe sleep apnea patients. There is newer simulators that are minimally invasive and expensive. And then there's surgery so see, perhaps remain the gold standard of therapy, except that adherence to therapy is low. In the past few decades, there has been zero comfort innovation in this market. Now, why is that here is the therapy low? Well, you're wearing a mask during sleep, and there's a tube and you're attached to your bedside table. Of course, it's uncomfortable. But if the doctor tells you that you're gonna get heart attacks and strokes, you'll end up using your machine, except that in the beginning of the night pressure is low while you fall asleep, pressure goes higher and higher. Halfway through the night, you realize the pressure is too much on your face, you rip the mask off, and you become a non ser and patient. Sima, our product is a patented AI enabled software that predicts and prevents apneas before they would happen. By doing so reduces the pressure of therapy makes it more comfortable for patients. If you think of your airway, like a party balloon in the beginning of blowing up a party balloon, you push really hard and then it gets easier, right? Same with the airway. If you know it's going to collapse, you need less pressure to keep it open. That's what CMF does. But let's go through the patient journey. patients are diagnosed with obstructive sleep apnea they're sent home with a trial CPAP machine. If within the first three months of use, you find the 30 consecutive day that for 70% of those days, they use the machine for more than four hours a night. Medicare covers the cost of the machine. And Medicare covers the cost of resupply consumables the to mask quarterly, yet, there is 40 to 50% of patients that do not do not meet that four hours criteria. improving adherence by using SEMA will increase the revenue for manufacturers will increase the revenue for dem ease in terms of selling devices every five years and the consumables quarterly PMEs will spend less labor cost talking to patients trying to convince them to use it for over four hours a night. And most importantly, patients will have a better quality of life. Now, why is 10% in adherence important, because it's equivalent. Not even considering the growth in this market is equivalent to $700 million a year more revenue for current manufacturers in the market. We have the software ready to go on any CPAP machine in the market. And of course by lowering the pressure of therapy, futuristic, wearable matter enabled machines could be possible. We first collected data from patients prove that you can predict apneas that was the first time that anyone had that had done that, then we use those predictions to actually prevent individual athletes in the first inhuman trial successfully did that as well. Our focus at that time wasn't to lower the pressure of therapy we spent 2023 Improving Sima and lowering the pressure of therapy and currently as I'm speaking to the patients that are enjoying using Sema, we have 50 More patients to go on comfort study that's just started. We're going to prove that we can lower the pressure of therapy without compromising efficacy, efficacy being ahi. In this case, HR is the number of avenues you get our like my father has obstructive apnea severe obstructive sleep apnea, he would get seven events an hour and CPAP would reduce that number. So ahi would be less by lowering the pressure. You were at the risk of compromising HIV and increasing it but see map doesn't let that happen. We're also doing a 200 patients study to quantify how much adherence we're improving in 2024. Speaking of comfort, reducing the pressure and comfort Amazing not compromising ahi there's a bit of a breaking news in this market. This paper came out of the lancet that's warning everyone that high pressure CPAP therapy could potentially lead to cardiovascular disease due to inflammation that it causes. patients with cancer. Patients with COPD that are on CPAP machines, they're all at risk of inflammation already so high, the authors have recommended reducing the pressure of therapy and compromising ahi you reduce the pressure, you get more apneas, you would be saved from the cardiovascular disease that may be coming. However, but the other comorbidities of obstructive sleep apnea, or are about to happen. What the C map do reduces the pressure of therapy does not compromise ha. This is an actual patient data that I'm showing you. And it's pure magic to be honest. Patients are also enjoying using Sima. I even heard from a partner that you know, the air coming out of the mask, the exhaust of air air flow that comes out of the mask of the partner used to wake her up, and she couldn't sleep well next to her husband, and that has reduced now and she's living better. Of course with AI comes personalization and we have strong IP in this area. Our first product would be installed on any CPAP machine in the market. It will work on the general population. Next step would be to add personalization. And the step after that would be to add digital health and other software as a service products to that our leadership team is pretty strong. Dr. Neil Smith is the founder of one of North America's largest privately owned sleep shops. Mr. Raj SoDI is a well known global leader in digital health and former President of Software as a Service at resume. Myself I have a PhD in Biomedical Engineering, specializing in respect mechanics, multiple patents in the field. Our Medical Advisory Board is even more impressive. Dr. Rena Mara, that's the head of Sleep Medicine at the University of Washington, doctors fietsen pin Zell at the Sheraton Institute of Berlin, which is basically the Mayo Clinic of Europe. These doctors write the guidelines for European and American doctors through European respiratory society and American Thoracic Society. We have multiple patents issued in the field and some pending in different geographies. We just filed the PCT for the personalization, patent and more patents in the line. We have an oversubscribed fully committed round. So we're not raising currently, this will find us to do the studies that I mentioned and lander manufacturing partners. We address patient adherence, which is the clear market impediments. We also do that by not compromising patient's health. It is a large and undeniably growing market. We've already demonstrated that CMAT works and we've protected our IP. I used to say that we lower the pressure therapy using AI to make it more comfortable. Now I can say that we're potentially also making therapy Safer for Patients. Thank you very much